146 related articles for article (PubMed ID: 38660876)
21. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].
Jin Y; Wang AY; Wang XB; Yang HZ; Liu X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of
Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
[TBL] [Abstract][Full Text] [Related]
23. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P;
Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
25. Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China.
Ding J; Su Y; Ruan Y; Li N; Meng Q; Yang J; Chen L; Liu C
Hematology; 2024 Dec; 29(1):2310960. PubMed ID: 38323781
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
27. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
28. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
30. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.
Short NJ; Rafei H; Daver N; Hwang H; Ning J; Jorgensen JL; Kadia TM; DiNardo CD; Wang SA; Jabbour E; Popat U; Oran B; Cortes J; Konopleva M; Yilmaz M; Issa GC; Kantarjian H; Ravandi F
Blood Adv; 2020 Dec; 4(24):6117-6126. PubMed ID: 33351107
[TBL] [Abstract][Full Text] [Related]
32. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
33. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
34. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
[TBL] [Abstract][Full Text] [Related]
35. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of MRD in AML].
Ishikawa Y
Rinsho Ketsueki; 2020; 61(9):1150-1159. PubMed ID: 33162510
[TBL] [Abstract][Full Text] [Related]
37. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; Paiva B; Martínez-Cuadrón D; Bergua JM; Vives S; Algarra L; Tormo M; Martinez P; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; Gil C; Lopez JL; Vidriales MB; Labrador J; Falantes JF; Sayas MJ; Ayala R; Martinez-Lopez J; Villar S; Calasanz MJ; Prosper F; San-Miguel JF; Sanz MÁ; Montesinos P
Blood Adv; 2021 Feb; 5(3):760-770. PubMed ID: 33560390
[TBL] [Abstract][Full Text] [Related]
38. [Minimal residual disease in AML].
Taga T
Rinsho Ketsueki; 2020; 61(4):343-349. PubMed ID: 32378579
[TBL] [Abstract][Full Text] [Related]
39. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
40. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]